Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$8.44M$8.44Mderived+349.8% vs Q4 2020 Net Income-$9.53M-$9.53MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$10,999,000N/M Operating Cash Flowderived-$10,944,000N/M Free Cash Flowderived-$11,286,000N/M Margins · derivedOperating margin-130.3%+530.9 pt vs Q4 2020
Net margin-112.9%+654.3 pt vs Q4 2020
ended Dec 31, 2021 · filed Mar 2, 2022 · 61 d after period end